Presenters were (clockwise, from top left): Zhijan Chen, PhD, Mark Dawson, MD, PhD, Melissa Davis, PhD, Karen Vousden, PhD, FAACR, Matthew Vander Heiden, MD, PhD, and Jonathan Weissman, PhD.
(Clockwise, top left) Lipika Goyal, MD, Vivek Subbiah, MD, Jeffrey Goh, MBBS, and Jermaine Coward, MBBS, PhD, presented during the Annual Meeting’s last Clinical Trials Plenary session.
Program Committee Chair Charles Swanton, MBPhD, FAACR, shares some of his selections from the day’s sessions to help plan your Annual Meeting experience.
Presenters Caroline Dive, BPharm, PhD, Alberto Bardelli, PhD, and Sarah-Jane Dawson, MBBS, PhD, discussed different uses for this evolving field.
(From left) Crystal L. Mackall, MD, Hagop M. Kantargian, MD, and Carl H. June, MD, PhD, FAACR, discussed how to decide between monoclonal antibodies, CAR-T therapies, or a combination.
(From left) Steven Goodman, MD, MHS, PhD, Mi-Ok Kim, PhD, and Motomi Mori, PhD, discussed current schools of thought regarding their use or misuse in studies.
“Now, more than ever, it is imperative that our innovative work continues, because patients with cancer around the world are counting on us,” said AACR CEO Margaret Foti, PhD, MD (hc).
Monday’s plenary features presentations from (clockwise, from left) Serena Nik-Zainal, MD, PhD, Ross L. Levine, MD, Jérôme Galon, PhD, and Garry P. Nolan, PhD.
Subscribe below to get email updates from AACRMeetingNews.org